Core Viewpoint - Morgan Stanley has downgraded the profit forecast for China Traditional Chinese Medicine from 2025 to 2030 by 10% to 14%, reflecting increased impairment provisions related to the price reduction of Chinese medicine formula granules [1] Group 1: Financial Performance - The target price has been reduced from HKD 1.6 to HKD 1.5, maintaining a "reduce" rating [1] - The company's performance continues to fall short of market expectations, and the quality of earnings has declined [1] Group 2: Investor Sentiment - The termination of a highly publicized transaction last year may negatively impact investors' perception of the company's governance [1] - Ongoing selling pressure on the stock is anticipated, as event-driven investors are likely to continue reducing their remaining holdings [1]
大行评级｜大摩：微降中国中药目标价至1.5港元 下调盈利预测